{"id":340610,"date":"2026-11-05T13:39:23","date_gmt":"2026-11-05T08:09:23","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=340610"},"modified":"2026-11-05T13:39:23","modified_gmt":"2026-11-05T08:09:23","slug":"rossari-biotech-share-price-target-2027","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/","title":{"rendered":"Rossari Biotech Share Price Target 2027: Is Rs 450 Realistic? Bull Case Points to Rs 547"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Rossari Biotech share price Rs 423.15 (5 November 2026). Base target Rs 450, bull Rs 547, downside risk Rs 337. PE 15.3. 52W range Rs 375.00 to Rs 654.00.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The Rossari Biotech share price target for 2027 is Rs 450, about 6.3% above the current price of Rs 423.15. The bull case is Rs 547, and the downside risk level, which is not a target, is Rs 337. The base case assumes earnings per share grow 6.8% a year, the pace seen from FY24 to FY26, with the stock holding its PE of 15.3. These are model-based estimates built from reported financials, not guaranteed outcomes.<\/p>\n<\/p><\/div>\n<p>Investors weighing a Rossari Biotech target price for 2027 should start with where the stock sits today. At Rs 423.15 on 5 November 2026, it is 35.3% below its 52-week high of Rs 654.00 and 12.8% above its 52-week low of Rs 375.00. That range spans 74% from low to high, so the entry point matters as much as the Rossari Biotech price forecast itself.<\/p>\n<p>This article builds the Rossari Biotech share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario states its assumptions, so you can trace how the base case, the bull case and the downside risk level were reached and test them against your own view.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=rossari-biotech-share-price-target-2027\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#Rossari_Biotech_Stock_Analysis_Company_Overview_and_Key_Stats\" title=\"Rossari Biotech Stock Analysis: Company Overview and Key Stats\">Rossari Biotech Stock Analysis: Company Overview and Key Stats<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#Why_Is_Rossari_Biotech_Share_Price_Target_Set_at_Rs_450_for_2027\" title=\"Why Is Rossari Biotech Share Price Target Set at Rs 450 for 2027?\">Why Is Rossari Biotech Share Price Target Set at Rs 450 for 2027?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#Earnings_Growth_Behind_the_Rossari_Biotech_Target_Price_Five_Years_of_Results\" title=\"Earnings Growth Behind the Rossari Biotech Target Price: Five Years of Results\">Earnings Growth Behind the Rossari Biotech Target Price: Five Years of Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#Margins_and_the_Latest_Quarter\" title=\"Margins and the Latest Quarter\">Margins and the Latest Quarter<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#Balance_Sheet_and_Cash_Flow\" title=\"Balance Sheet and Cash Flow\">Balance Sheet and Cash Flow<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#Valuation_Check_for_the_Rossari_Biotech_Stock_Target_PE_Price_to_Book_and_ROE\" title=\"Valuation Check for the Rossari Biotech Stock Target: PE, Price to Book and ROE\">Valuation Check for the Rossari Biotech Stock Target: PE, Price to Book and ROE<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#Shareholding_Pattern_and_Institutional_Holding\" title=\"Shareholding Pattern and Institutional Holding\">Shareholding Pattern and Institutional Holding<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#Rossari_Biotech_Share_Price_Targets_for_the_Short_Term_and_12_Months\" title=\"Rossari Biotech Share Price Targets for the Short Term and 12 Months\">Rossari Biotech Share Price Targets for the Short Term and 12 Months<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#Short_Term_Rossari_Biotech_Stock_Target_Levels_Technical_Setup\" title=\"Short Term Rossari Biotech Stock Target Levels: Technical Setup\">Short Term Rossari Biotech Stock Target Levels: Technical Setup<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#12_Month_Rossari_Biotech_Target_Price_for_2027\" title=\"12 Month Rossari Biotech Target Price for 2027\">12 Month Rossari Biotech Target Price for 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#How_EPS_Growth_and_PE_Multiple_Change_the_Rossari_Biotech_Target_Price\" title=\"How EPS Growth and PE Multiple Change the Rossari Biotech Target Price\">How EPS Growth and PE Multiple Change the Rossari Biotech Target Price<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#Bull_Case_and_Downside_Risk_for_Rossari_Biotech_Stock_Target_in_2027\" title=\"Bull Case and Downside Risk for Rossari Biotech Stock Target in 2027\">Bull Case and Downside Risk for Rossari Biotech Stock Target in 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#Bull_Case_Rs_547\" title=\"Bull Case Rs 547\">Bull Case Rs 547<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#Downside_Risk_Level_Rs_337\" title=\"Downside Risk Level Rs 337\">Downside Risk Level Rs 337<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#Key_Risks_to_the_Rossari_Biotech_Target_Price_for_2027\" title=\"Key Risks to the Rossari Biotech Target Price for 2027\">Key Risks to the Rossari Biotech Target Price for 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#Growth_Slowdown_Risk_for_the_Rossari_Biotech_Price_Target\" title=\"Growth Slowdown Risk for the Rossari Biotech Price Target\">Growth Slowdown Risk for the Rossari Biotech Price Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#Liquidity_and_Size_Risk\" title=\"Liquidity and Size Risk\">Liquidity and Size Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#Valuation_and_Margin_Risk\" title=\"Valuation and Margin Risk\">Valuation and Margin Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#Market_and_Technical_Risk\" title=\"Market and Technical Risk\">Market and Technical Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#How_to_Invest_in_Rossari_Biotech\" title=\"How to Invest in Rossari Biotech\">How to Invest in Rossari Biotech<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#FAQs_on_Rossari_Biotech_Share_Price_Target_2027\" title=\"FAQs on Rossari Biotech Share Price Target 2027\">FAQs on Rossari Biotech Share Price Target 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#What_is_the_Rossari_Biotech_share_price_target_for_2027\" title=\"What is the Rossari Biotech share price target for 2027?\">What is the Rossari Biotech share price target for 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#What_is_the_Rossari_Biotech_share_price_today\" title=\"What is the Rossari Biotech share price today?\">What is the Rossari Biotech share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#Is_Rossari_Biotech_a_buy_or_sell_at_the_current_price\" title=\"Is Rossari Biotech a buy or sell at the current price?\">Is Rossari Biotech a buy or sell at the current price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#What_are_the_bull_case_target_and_downside_risk_level_for_Rossari_Biotech_shares\" title=\"What are the bull case target and downside risk level for Rossari Biotech shares?\">What are the bull case target and downside risk level for Rossari Biotech shares?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#What_are_the_main_risks_to_the_Rossari_Biotech_price_target\" title=\"What are the main risks to the Rossari Biotech price target?\">What are the main risks to the Rossari Biotech price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#What_is_the_PE_ratio_of_Rossari_Biotech_and_how_does_it_compare_with_the_industry\" title=\"What is the PE ratio of Rossari Biotech and how does it compare with the industry?\">What is the PE ratio of Rossari Biotech and how does it compare with the industry?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#Who_owns_Rossari_Biotech_and_what_is_the_promoter_holding\" title=\"Who owns Rossari Biotech, and what is the promoter holding?\">Who owns Rossari Biotech, and what is the promoter holding?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/univest.in\/blogs-2\/rossari-biotech-share-price-target-2027\/#What_were_Rossari_Biotechs_latest_quarterly_results\" title=\"What were Rossari Biotech&#8217;s latest quarterly results?\">What were Rossari Biotech&#8217;s latest quarterly results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Rossari_Biotech_Stock_Analysis_Company_Overview_and_Key_Stats\"><\/span><strong>Rossari Biotech Stock Analysis: Company Overview and Key Stats<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Rossari Biotech (NSE: ROSSARI) has a market capitalisation of Rs 2,337 crore. In FY26 it reported revenue of Rs 2,419 crore and net profit of Rs 149.21 crore. The table collects the figures the Rossari Biotech share price target is built on.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>Company<\/td>\n<td><a href=\"https:\/\/univest.in\/stocks\/rossari\/rossari-biotech-ltd-share-price-today\">Rossari Biotech<\/a><\/td>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>ROSSARI<\/td>\n<\/tr>\n<tr>\n<td>CMP (5 November 2026)<\/td>\n<td>Rs 423.15<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 654.00<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 375.00<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 2,337 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio (TTM)<\/td>\n<td>15.30<\/td>\n<\/tr>\n<tr>\n<td>Industry PE<\/td>\n<td>32.55<\/td>\n<\/tr>\n<tr>\n<td>Price to Book<\/td>\n<td>1.66<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>10.85%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.28<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>Rs 27.57<\/td>\n<\/tr>\n<tr>\n<td>Dividend Yield<\/td>\n<td>0.12%<\/td>\n<\/tr>\n<tr>\n<td>12-Month Base Target<\/td>\n<td>Rs 450<\/td>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 547<\/td>\n<\/tr>\n<tr>\n<td>Downside Risk Level (not a target)<\/td>\n<td>Rs 337<\/td>\n<\/tr>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Why_Is_Rossari_Biotech_Share_Price_Target_Set_at_Rs_450_for_2027\"><\/span><strong>Why Is Rossari Biotech Share Price Target Set at Rs 450 for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The arithmetic is short. Trailing EPS of Rs 27.57 grown for one year gives a forward EPS estimate of Rs 29.44, and multiplying it by the unchanged PE of 15.30 gives the Rs 450 base-case Rossari Biotech stock target. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Earnings_Growth_Behind_the_Rossari_Biotech_Target_Price_Five_Years_of_Results\"><\/span><strong>Earnings Growth Behind the Rossari Biotech Target Price: Five Years of Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Rossari Biotech grew revenue from Rs 1,495 crore in FY22 to Rs 2,419 crore in FY26, a compound annual growth rate of 12.8%. Net profit grew more slowly, from Rs 97.69 crore to Rs 149.21 crore (11.2% a year), which points to margin pressure alongside the sales growth.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Financial Year<\/th>\n<th>Revenue (Rs Cr)<\/th>\n<th>Net Profit (Rs Cr)<\/th>\n<th>EPS (Rs)<\/th>\n<th>Dividend per Share (Rs)<\/th>\n<\/tr>\n<tr>\n<td>FY22<\/td>\n<td>1,494.97<\/td>\n<td>97.69<\/td>\n<td>17.70<\/td>\n<td>0.50<\/td>\n<\/tr>\n<tr>\n<td>FY23<\/td>\n<td>1,661.37<\/td>\n<td>107.26<\/td>\n<td>19.38<\/td>\n<td>0.50<\/td>\n<\/tr>\n<tr>\n<td>FY24<\/td>\n<td>1,838.00<\/td>\n<td>130.69<\/td>\n<td>23.62<\/td>\n<td>0.50<\/td>\n<\/tr>\n<tr>\n<td>FY25<\/td>\n<td>2,084.30<\/td>\n<td>136.38<\/td>\n<td>24.63<\/td>\n<td>0.50<\/td>\n<\/tr>\n<tr>\n<td>FY26<\/td>\n<td>2,418.74<\/td>\n<td>149.21<\/td>\n<td>26.93<\/td>\n<td>0.50<\/td>\n<\/tr>\n<\/table>\n<p>FY26 revenue growth was 16.0%, faster than the four-year average of 12.8%, and net profit moved up 9.4%. EPS rose from Rs 23.62 in FY24 to Rs 26.93 in FY26. The FY27 outlook depends on whether that EPS estimate keeps compounding.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Margins_and_the_Latest_Quarter\"><\/span><strong>Margins and the Latest Quarter<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Rossari Biotech converted 6.2% of FY26 revenue into net profit, against 6.5% in FY25, within a five-year range of 6.2% to 7.1%. EBITDA margin was 12.8% in FY26 versus 13.0% in FY25.<\/p>\n<p>In the September 2026 quarter, revenue was Rs 698.16 crore, up 18.8% from the same quarter a year earlier, while net profit of Rs 38.91 crore was up 5.5%. EBITDA came in at Rs 87.58 crore, up 19.1% year on year. The next quarterly result is the first test of whether the earnings assumption holds.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Balance_Sheet_and_Cash_Flow\"><\/span><strong>Balance Sheet and Cash Flow<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Debt to equity stands at 0.28, and shareholders&#8217; equity grew from Rs 805.16 crore in FY22 to Rs 1,333 crore in FY26. Operating cash flow in FY26 was Rs 65.07 crore against capital expenditure of Rs 264.67 crore, leaving negative free cash flow of Rs 199.60 crore. In FY25 free cash flow was negative at Rs 21.07 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_Check_for_the_Rossari_Biotech_Stock_Target_PE_Price_to_Book_and_ROE\"><\/span><strong>Valuation Check for the Rossari Biotech Stock Target: PE, Price to Book and ROE<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At a PE of 15.30 against an industry PE of 32.55, Rossari Biotech trades at a discount to its industry. Price to book is 1.66 on a book value of Rs 254.11 per share, and return on equity is 10.85%. A PE of 15.30 equals an earnings yield of 6.5%, and the FY26 dividend of Rs 0.50 per share gives a yield of 0.12%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Shareholding_Pattern_and_Institutional_Holding\"><\/span><strong>Shareholding Pattern and Institutional Holding<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Promoters held 68.14% of Rossari Biotech in September 2026, and promoter holding has stayed near 68.14% since September 2025. Foreign institutional investors (FII) held 1.84% and domestic institutions (DII) held 14.19%, which puts total institutional holding at 16.03%. FII holding fell from 2.69% in September 2025 to 1.84% in September 2026. Public shareholders own the remaining 15.83%. A meaningful institutional holding adds a layer of research coverage and trading depth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Rossari_Biotech_Share_Price_Targets_for_the_Short_Term_and_12_Months\"><\/span><strong>Rossari Biotech Share Price Targets for the Short Term and 12 Months<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Short_Term_Rossari_Biotech_Stock_Target_Levels_Technical_Setup\"><\/span><strong>Short Term Rossari Biotech Stock Target Levels: Technical Setup<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At Rs 423.15 on 5 November 2026, Rossari Biotech trades below its 50-day simple moving average of Rs 439.42 and below its 200-day exponential moving average of Rs 497.29. The 14-day RSI reads 44.3, which is neutral territory, and the MACD line sits above its signal line. The nearest resistance level is Rs 439.42 (50-day simple moving average) and the nearest support is Rs 375.00 (52-week low). A sustained move above Rs 439.42 would improve the short-term setup, while a close below Rs 375.00 would shift attention to the next support.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"12_Month_Rossari_Biotech_Target_Price_for_2027\"><\/span><strong>12 Month Rossari Biotech Target Price for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 12-month target of Rs 450 means a move of 6.3% up from Rs 423.15 over the next 12 months. It would still leave the stock 31.2% below its 52-week high of Rs 654.00.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_EPS_Growth_and_PE_Multiple_Change_the_Rossari_Biotech_Target_Price\"><\/span><strong>How EPS Growth and PE Multiple Change the Rossari Biotech Target Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>EPS Growth<\/th>\n<th>PE 12.24<\/th>\n<th>PE 15.30<\/th>\n<th>PE 17.59<\/th>\n<\/tr>\n<tr>\n<td>0.0% (EPS Rs 27.57)<\/td>\n<td>Rs 337<\/td>\n<td>Rs 422<\/td>\n<td>Rs 485<\/td>\n<\/tr>\n<tr>\n<td>6.8% (EPS Rs 29.44)<\/td>\n<td>Rs 360<\/td>\n<td>Rs 450<\/td>\n<td>Rs 518<\/td>\n<\/tr>\n<tr>\n<td>12.8% (EPS Rs 31.09)<\/td>\n<td>Rs 381<\/td>\n<td>Rs 476<\/td>\n<td>Rs 547<\/td>\n<\/tr>\n<\/table>\n<p>Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Rossari Biotech price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bull_Case_and_Downside_Risk_for_Rossari_Biotech_Stock_Target_in_2027\"><\/span><strong>Bull Case and Downside Risk for Rossari Biotech Stock Target in 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Bull_Case_Rs_547\"><\/span><strong>Bull Case Rs 547<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The bull case Rossari Biotech price target needs EPS growth of 12.8%, which lifts forward EPS to Rs 31.09, and a PE multiple that rises 15% to 17.59. That gives Rs 547, 29.3% above the current price and below the 52-week high of Rs 654.00.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Downside_Risk_Level_Rs_337\"><\/span><strong>Downside Risk Level Rs 337<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The downside risk level is not a target. It assumes EPS stays flat at Rs 27.57 and the PE falls 20% to 12.24. That gives Rs 337, 20.4% below the current price and below the 52-week low of Rs 375.00.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Scenario<\/th>\n<th>EPS Growth<\/th>\n<th>PE Multiple<\/th>\n<th>Price (Rs)<\/th>\n<th>Change vs CMP<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>12.8%<\/td>\n<td>17.59<\/td>\n<td>Rs 547<\/td>\n<td>+29.3%<\/td>\n<\/tr>\n<tr>\n<td>Base Case<\/td>\n<td>6.8%<\/td>\n<td>15.30<\/td>\n<td>Rs 450<\/td>\n<td>+6.3%<\/td>\n<\/tr>\n<tr>\n<td>Downside Risk<\/td>\n<td>0.0%<\/td>\n<td>12.24<\/td>\n<td>Rs 337<\/td>\n<td>-20.4%<\/td>\n<\/tr>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_the_Rossari_Biotech_Target_Price_for_2027\"><\/span><strong>Key Risks to the Rossari Biotech Target Price for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Growth_Slowdown_Risk_for_the_Rossari_Biotech_Price_Target\"><\/span><strong>Growth Slowdown Risk for the Rossari Biotech Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Revenue in the September 2026 quarter was up 18.8% year on year, and FY26 revenue growth was 16.0%. If growth slows from here, the EPS estimate behind the Rossari Biotech stock target will need revising.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Liquidity_and_Size_Risk\"><\/span><strong>Liquidity and Size Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Rossari Biotech has a market capitalisation of Rs 2,337 crore. Institutional holding is 16.03%, and promoters hold 68.14%. Stocks of this size can move sharply on small volumes, and exits can take longer than entries.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_and_Margin_Risk\"><\/span><strong>Valuation and Margin Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Net margin was 6.2% in FY26, so a small slip in costs moves profit noticeably. At a PE of 15.30 versus an industry PE of 32.55, a de-rating toward the downside-risk PE of 12.24 would cut the price even if earnings hold.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Market_and_Technical_Risk\"><\/span><strong>Market and Technical Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Technical indicators add short-term risk: the 14-day RSI is 44.3 and the MACD sits above its signal line. A broad fall in the <a href=\"https:\/\/univest.in\/indices\/nifty-50\/nifty-50-share-price-today\">Nifty 50<\/a> or the <a href=\"https:\/\/univest.in\/indices\/sensex\/sensex-share-price-today\">Sensex<\/a> can override company fundamentals for weeks at a time.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Rossari_Biotech\"><\/span><strong>How to Invest in Rossari Biotech<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Start with the live price and volume. Any Rossari Biotech share price target is only as current as the data behind it, and the data here is as of 5 November 2026, so refresh the Rs 423.15 price before acting on any level.<\/p>\n<p>Next, review the fundamentals yourself. The Univest Screener lets you check Rossari Biotech&#8217;s PE, ROE, debt and shareholding in one place.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check Rossari Biotech fundamentals on the Univest Screener<\/strong><\/a><\/p>\n<p>Then compare the three Rossari Biotech target price scenarios with your own view. If you expect EPS growth below 6.8%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.<\/p>\n<p>Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.<\/p>\n<p>Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Rossari Biotech live price and get daily stock recommendations.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Rossari Biotech share price target for 2027 is Rs 450 in the base case, with Rs 547 as the bull case. The support for that view is arithmetic you can check: EPS grew 6.8% a year over FY24 to FY26, and the stock trades at a PE of 15.30. The risks are equally concrete, including a net margin of just 6.2% that leaves profit sensitive to costs and a downside scenario that cuts the price 20% if earnings stall. Use these numbers as a framework, check them against the latest filings, and size any position to your own risk appetite.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Rossari_Biotech_Share_Price_Target_2027\"><\/span><strong>FAQs on Rossari Biotech Share Price Target 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Rossari_Biotech_share_price_target_for_2027\"><\/span><strong>What is the Rossari Biotech share price target for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The base-case Rossari Biotech share price target for 2027 is Rs 450, which is 6.3% above the price of Rs 423.15 on 5 November 2026. The bull case is Rs 547 and the downside risk level, which is not a target, is Rs 337. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Rossari_Biotech_share_price_today\"><\/span><strong>What is the Rossari Biotech share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of 5 November 2026, 11:37 AM IST, Rossari Biotech (NSE: ROSSARI) trades at Rs 423.15, up 0.65% on the day. That is 35.3% below the 52-week high of Rs 654.00 and 12.8% above the 52-week low of Rs 375.00. The market capitalisation of Rs 2,337 crore places it among small-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Rossari_Biotech_a_buy_or_sell_at_the_current_price\"><\/span><strong>Is Rossari Biotech a buy or sell at the current price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The data points both ways. On the positive side, EPS has grown 6.8% a year over FY24 to FY26 and the base case implies 6.3% upside; on the cautious side, the net margin is a thin 6.2%, and the downside risk level of Rs 337 is 20% below the current price. Whether Rossari Biotech fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_bull_case_target_and_downside_risk_level_for_Rossari_Biotech_shares\"><\/span><strong>What are the bull case target and downside risk level for Rossari Biotech shares?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The bull case in the Rossari Biotech share price target for 2027 is Rs 547, which assumes 12.8% EPS growth and a PE of 17.59, a 15% re-rating from today&#8217;s multiple. That is 29.3% above the current price and below the 52-week high of Rs 654.00. The downside risk level is Rs 337, which assumes flat EPS and a PE of 12.24, 20% lower than today. It sits 20.4% below the current price and below the 52-week low of Rs 375.00, and it marks a risk to watch, not a target.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_risks_to_the_Rossari_Biotech_price_target\"><\/span><strong>What are the main risks to the Rossari Biotech price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Four risks matter most for the Rossari Biotech share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. With a market capitalisation of Rs 2,337 crore, the stock can move sharply on small volumes, and exits can take longer than entries. A fall to the downside-risk PE of 12.24 would cut the price even if earnings hold.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_PE_ratio_of_Rossari_Biotech_and_how_does_it_compare_with_the_industry\"><\/span><strong>What is the PE ratio of Rossari Biotech and how does it compare with the industry?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The PE ratio of Rossari Biotech is 15.30, against an industry PE of 32.55, which is a discount to the industry. Price to book is 1.66 and return on equity is 10.85%, and the PE equals an earnings yield of 6.5%. The base case holds the PE unchanged, so the Rossari Biotech share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Who_owns_Rossari_Biotech_and_what_is_the_promoter_holding\"><\/span><strong>Who owns Rossari Biotech, and what is the promoter holding?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Promoters held 68.14% of Rossari Biotech in September 2026. FII held 1.84%, DII held 14.19% and the public held 15.83%. Together the two institutional groups hold 16.03%. Shareholding is filed every quarter, so it is worth rechecking after each result.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Rossari_Biotechs_latest_quarterly_results\"><\/span><strong>What were Rossari Biotech&#8217;s latest quarterly results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> In the September 2026 quarter, Rossari Biotech reported revenue of Rs 698.16 crore (up 18.8% year on year) and net profit of Rs 38.91 crore (up 5.5%). For comparison, FY26 full-year revenue growth was 16.0% and net profit moved up 9.4%. Each new quarter either supports or weakens the EPS growth of 6.8% assumed in the base case.<\/p>\n<p><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Rossari Biotech share price target for 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The base-case Rossari Biotech share price target for 2027 is Rs 450, which is 6.3% above the price of Rs 423.15 on 5 November 2026. The bull case is Rs 547 and the downside risk level, which is not a target, is Rs 337. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.\"}},{\"@type\":\"Question\",\"name\":\"What is the Rossari Biotech share price today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of 5 November 2026, 11:37 AM IST, Rossari Biotech (NSE: ROSSARI) trades at Rs 423.15, up 0.65% on the day. That is 35.3% below the 52-week high of Rs 654.00 and 12.8% above the 52-week low of Rs 375.00. The market capitalisation of Rs 2,337 crore places it among small-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.\"}},{\"@type\":\"Question\",\"name\":\"Is Rossari Biotech a buy or sell at the current price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The data points both ways. On the positive side, EPS has grown 6.8% a year over FY24 to FY26 and the base case implies 6.3% upside; on the cautious side, the net margin is a thin 6.2%, and the downside risk level of Rs 337 is 20% below the current price. Whether Rossari Biotech fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.\"}},{\"@type\":\"Question\",\"name\":\"What are the bull case target and downside risk level for Rossari Biotech shares?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The bull case in the Rossari Biotech share price target for 2027 is Rs 547, which assumes 12.8% EPS growth and a PE of 17.59, a 15% re-rating from today's multiple. That is 29.3% above the current price and below the 52-week high of Rs 654.00. The downside risk level is Rs 337, which assumes flat EPS and a PE of 12.24, 20% lower than today. It sits 20.4% below the current price and below the 52-week low of Rs 375.00, and it marks a risk to watch, not a target.\"}},{\"@type\":\"Question\",\"name\":\"What are the main risks to the Rossari Biotech price target?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Four risks matter most for the Rossari Biotech share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. With a market capitalisation of Rs 2,337 crore, the stock can move sharply on small volumes, and exits can take longer than entries. A fall to the downside-risk PE of 12.24 would cut the price even if earnings hold.\"}},{\"@type\":\"Question\",\"name\":\"What is the PE ratio of Rossari Biotech and how does it compare with the industry?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The PE ratio of Rossari Biotech is 15.30, against an industry PE of 32.55, which is a discount to the industry. Price to book is 1.66 and return on equity is 10.85%, and the PE equals an earnings yield of 6.5%. The base case holds the PE unchanged, so the Rossari Biotech share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.\"}},{\"@type\":\"Question\",\"name\":\"Who owns Rossari Biotech, and what is the promoter holding?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Promoters held 68.14% of Rossari Biotech in September 2026. FII held 1.84%, DII held 14.19% and the public held 15.83%. Together the two institutional groups hold 16.03%. Shareholding is filed every quarter, so it is worth rechecking after each result.\"}},{\"@type\":\"Question\",\"name\":\"What were Rossari Biotech's latest quarterly results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"In the September 2026 quarter, Rossari Biotech reported revenue of Rs 698.16 crore (up 18.8% year on year) and net profit of Rs 38.91 crore (up 5.5%). For comparison, FY26 full-year revenue growth was 16.0% and net profit moved up 9.4%. Each new quarter either supports or weakens the EPS growth of 6.8% assumed in the base case.\"}}]}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Rossari Biotech share price target 2027: base Rs 450, bull Rs 547, downside risk level Rs 337, built from reported earnings, valuation and shareholding data.<\/p>\n","protected":false},"author":35,"featured_media":340609,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[1019],"class_list":["post-340610","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["340609"],"rank_math_title":["Rossari Biotech Share Price Target 2027: 6.3% Upside, Bull Rs 547"],"rank_math_description":["The Rossari Biotech share price target for 2027 is Rs 450 versus Rs 423.15 today. Bull case, downside risk, earnings trend and risks explained. November 2026."],"rank_math_focus_keyword":["Rossari Biotech share price target | Density Target: 1.2 to 1.5%"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/rossari-biotech-share-price-target-2027-is-rs-450-realistic-bull-case-points-to.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/340610","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=340610"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/340610\/revisions"}],"predecessor-version":[{"id":340611,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/340610\/revisions\/340611"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/340609"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=340610"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=340610"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=340610"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}